{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T13:26:08Z","timestamp":1792070768352,"version":"4.4.0"},"reference-count":30,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/501100002447","name":"Catholic University of Daegu","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002447","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Metabolism Res"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Glucagon\u2010like peptide\u20101 receptor agonists (GLP\u20101 RAs) are widely used for metabolic disorders, but emerging safety concerns include alopecia and reproductive or endocrine\u2010related adverse events (AEs). This study investigated the association between specific GLP\u20101 RAs and these endocrine\u2010related AEs using a large\u2010scale pharmacovigilance database.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>This study analysed the U.S. FDA Adverse Event Reporting System (FAERS) data (Q2 2022\u2013Q2 2025) for six GLP\u20101 Ras (exenatide, lixisenatide, liraglutide, dulaglutide, semaglutide, and tirzepatide) to identify alopecia\u2010 and reproductive or endocrine\u2013related a AEs. Disproportionality analyses were conducted using crude and adjusted reporting odds ratios (cROR and aROR) from logistic regression controlling for potential confounding factors. Sensitivity analyses with positive and negative controls were used to validate the signal robustness.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 1276 alopecia\u2010related and 759 reproductive or endocrine\u2013related cases were identified. Semaglutide showed significant positive associations with alopecia (aROR 1.23 [1.11\u20131.35]) and reproductive\/hormonal disorders, including polycystic ovary syndrome (aROR 6.59 [3.73\u201311.64]) and menstrual abnormalities. In contrast, dulaglutide and tirzepatide demonstrated negative associations for several reproductive outcomes (e.g.,\u00a0dysmenorrhoea, amenorrhoea, heavy menstrual bleeding), indicating lower reporting odds in this dataset. Sensitivity analyses using control drugs confirmed the consistency and specificity of these findings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This real\u2010world pharmacovigilance study identified agent\u2010specific differences in the endocrine and dermatologic safety profiles of GLP\u20101 RAs. While semaglutide exhibited disproportionate reporting for alopecia and hormonal imbalance, dulaglutide and tirzepatide showed lower or non\u2010significant disproportionality signals for these events. These results highlight the need for personalised agent selection and continued pharmacovigilance to optimise long\u2010term patient safety.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/dmrr.70163","type":"journal-article","created":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T16:13:17Z","timestamp":1774541597000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Not All GLP\u20101 Receptor Agonists Are Alike: Real\u2010World Evidence of Differential Endocrine and Dermatologic Safety"],"prefix":"10.1002","volume":"42","author":[{"given":"Nai","family":"Lee","sequence":"first","affiliation":[{"name":"College of Pharmacy Daegu Catholic University  Gyeongsan Gyeongsangbuk\u2010do South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9809-7351","authenticated-orcid":false,"given":"Yun","family":"Kim","sequence":"additional","affiliation":[{"name":"College of Pharmacy Daegu Catholic University  Gyeongsan Gyeongsangbuk\u2010do South Korea"},{"name":"Convergence Research Institute for Biomedical Sciences Daegu Catholic University  Gyeongsan Gyeongsangbuk\u2010do South\u00a0Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,3,26]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1530\/EC\u201021\u20100130"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2019.09.010"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.1032199"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10557\u2010024\u201007613\u2010w"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdin.2026.01.014"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S484531"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa285"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/GME.0000000000002621"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2021.05.011"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/0026\u20100495(91)90199\u20107"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12185915"},{"key":"e_1_2_12_13_1","unstructured":"M. R. M.Center What's an 'Ozempic Baby'?."},{"key":"e_1_2_12_14_1","unstructured":"C.Clinic Ozempic Babies\u2019: How GLP\u20101 Agonists Affect Fertility https:\/\/health.clevelandclinic.org\/ozempic\u2010babies."},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264\u2010024\u201001423\u20107"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264\u2010024\u201001421\u20109"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2025.06.012"},{"key":"e_1_2_12_18_1","volume-title":"Dermatology Times","author":"Kobren S. D.","year":"2023"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.5826\/dpc.0701a01"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12010145"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1530\/JOE\u201013\u20100414"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1080\/19396368.2016.1177619"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgae584"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1080\/20565623.2025.2483607"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14944"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12958\u2010025\u201001425\u20109"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12144575"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2025.1529703"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2024.123310"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2025.177827"},{"key":"e_1_2_12_31_1","doi-asserted-by":"publisher","DOI":"10.3389\/fdsfr.2023.1323057"}],"container-title":["Diabetes\/Metabolism Research and Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/dmrr.70163","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/dmrr.70163","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/dmrr.70163","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T16:23:12Z","timestamp":1783009392000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/dmrr.70163"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,26]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10.1002\/dmrr.70163"],"URL":"https:\/\/doi.org\/10.1002\/dmrr.70163","archive":["Portico"],"relation":{},"ISSN":["1520-7552","1520-7560"],"issn-type":[{"value":"1520-7552","type":"print"},{"value":"1520-7560","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,26]]},"assertion":[{"value":"2025-12-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-17","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70163"}}